In the infectious disease space what kind of changes does Truenat RT-PCR bring in for the past several years? How were those learning used in COVID-19? The manufacturing capacity has been increased five fold, from the existing 70,000 tests per day to over 3.5 lakh tests per day that will ensure the uninterrupted availability of Truenat test kits both in the domestic and global markets for COVID and multiple diseases. Looking at the growing global demand for point -of-care molecular testing, we launched a new manufacturing facility in Goa this year. Today, more than 4000 Truenat machines are being used across the private and public sector for COVID-19, TB, hepatitis, H1N1 and other diseases testing all over India. It has also been the largest single brand in the COVID testing space in India. We have been working at the front of the pandemic from the beginning and Truenat launched in 2013 has played a significant role in India’s fight against COVID-19 by expanding access to RT PCR testing in rural, resource-limited geographies across the country. Soon more such machines were ordered both by state governments and the private sector. While about 700 machines were already available in the private and public sector, the Union health ministry decided to repurpose the 1512 machines they had ordered under the TB program for COVID testing. Also, our Truenat test for COVID-19 was among the early tests to be approved by ICMR.
However, there was limited capacity available in the early stages for conducting RT PCR tests and Truenat was the only platform that could enable RT-PCR testing across the country. The outbreak of COVID-19 dramatically increased the need for RT-PCR tests that has resulted in the market size suddenly growing many folds. Truenat RT- PCR is expected to become more of a routine clinical diagnostics tool not only for COVID, but for a wide range of infectious diseases in the near future in an interview with ETHealthworld's Prathiba Raju.Ĭan you elaborate on the crucial role Truenat RT- PCR is making in COVID-19 diagnosis? Have you scaled it up specifically for the virus ? Sriram Natarajan, Founder, Director and CEO, Molbio Diagnostics, elucidates on how the outbreak of COVID-19 has accelerated the field of molecular diagnostics.
0 kommentar(er)
